An open label trial to investigate the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), Immunoglobulin-G, in patients with primary immunodeficiency disease

Trial Profile

An open label trial to investigate the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), Immunoglobulin-G, in patients with primary immunodeficiency disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top